Female Sexual Health — Cost, Top Hospitals & Success Rates | MyMedicPlus

Female sexual health encompasses a woman's physical, emotional, psychological, and relational capacity for sexual wellbeing throughout her lifespan. Sexual health problems in women are common, affecting an estimated 40–45% of women at some point, yet remain significantly underdiagnosed and undertreated due to persistent stigma and limited clinician training in this specialty area.

The female sexual response cycle — desire, arousal, plateau, orgasm, and resolution — is governed by a complex interplay of hormonal, neurological, vascular, and psychological factors. Disorders can arise from disruption at any stage. The most widely used classification (DSM-5 and ICD-11) categorises female sexual dysfunctions into: hypoactive sexual desire/arousal disorder (HSDD/FSIAD), female orgasmic disorder (FOD), genitopelvic pain/penetration disorder (GPPPD) — which incorporates historic diagnoses of vaginismus and dyspareunia — and sexual interest/arousal disorder.

Hormones play a central role. Estrogen maintains vaginal lubrication, elasticity, and mucosal integrity; estrogen deficiency (menopause, surgical oophorectomy, breastfeeding) causes vulvovaginal atrophy and dyspareunia. Testosterone, produced in the ovaries and adrenal glands, influences libido; declining testosterone after natural or surgical menopause is associated with reduced sexual desire. Prolactin hypersecretion (pituitary adenoma) and thyroid dysfunction can suppress sexual function.

Psychological determinants — anxiety, depression, body image, relationship quality, trauma history, and past sexual abuse — account for the majority of female sexual dysfunction in reproductive-age women. A multidisciplinary approach integrating gynaecology, sexual medicine, psychosexual therapy, and pelvic floor physiotherapy is the evidence-based standard for comprehensive assessment and treatment.

Female sexual health services address the following conditions:

• Hypoactive Sexual Desire Disorder (HSDD) / Female Sexual Interest/Arousal Disorder (FSIAD): Persistently low or absent sexual desire causing personal distress. The most prevalent female sexual dysfunction, affecting approximately 10% of premenopausal women and up to 50% of postmenopausal women.
• Genitopelvic Pain/Penetration Disorder (GPPPD): Combines vaginismus (involuntary pelvic floor contraction preventing penetration) and dyspareunia (genital pain during intercourse). Includes vulvodynia — chronic vulvar pain without identifiable cause — affecting 8–16% of women.
• Female Orgasmic Disorder (FOD): Absent, infrequent, or markedly reduced orgasm intensity causing significant distress. Primary (lifelong) and secondary (acquired) subtypes have different aetiologies and treatment approaches.
• Vulvovaginal Atrophy (VVA) / Genitourinary Syndrome of Menopause (GSM): Estrogen-deficiency-related changes causing vaginal dryness, thinning, and dyspareunia, affecting 50–80% of postmenopausal women.
• Sexual dysfunction secondary to cancer treatment: Chemotherapy, pelvic radiotherapy, and hormonal therapies for breast/gynaecological cancers commonly cause sexual health complications requiring specialised rehabilitation.
• Sexual trauma and PTSD: Survivors of sexual assault or childhood abuse who experience significant sexual dysfunction benefit from trauma-informed psychosexual therapy.

Any woman experiencing distress related to her sexual health is eligible for assessment and care. There are no age restrictions — female sexual dysfunction occurs across the lifespan from adolescence through older adulthood. The following should prompt specialist referral:

• Persistent loss of sexual desire causing personal or relationship distress for ≥6 months
• Pain during or after intercourse (dyspareunia) or inability to achieve penetration (vaginismus/GPPPD)
• Inability to achieve orgasm despite adequate stimulation (primary or acquired FOD)
• Symptoms of vulvovaginal atrophy — vaginal dryness, burning, discharge changes, urinary symptoms — particularly in perimenopause or postmenopause
• Sexual health concerns arising during pregnancy, postpartum, or breastfeeding
• Sexual dysfunction following pelvic surgery, cancer treatment, or gynaecological conditions (endometriosis, PCOS, fibroids)
• Relationship conflict attributable to sexual health differences

Initial assessment includes a detailed sexual history, medical history review, gynaecological examination (including vulvoscopy where indicated), and targeted investigations: hormone panel (FSH, LH, estradiol, total/free testosterone, SHBG, prolactin, TSH), fasting glucose, and validated psychometric tools such as the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R).

Treatment is individualised based on the specific diagnosis, contributing factors, and patient preferences:

Pharmacological Treatments:

• Flibanserin (Addyi): FDA-approved for HSDD in premenopausal women. A daily oral 5-HT1A agonist / 5-HT2A antagonist that modulates central sexual pathways. Increases satisfying sexual events by approximately one additional event per month vs placebo. Requires abstinence from alcohol due to hypotension risk.
• Bremelanotide (Vyleesi): FDA-approved self-injectable melanocortin receptor agonist for premenopausal HSDD. Administered subcutaneously 45 minutes before anticipated sexual activity. Improves sexual desire and reduces distress.
• Topical estrogen (cream, pessary, ring): First-line for vulvovaginal atrophy/GSM. Local estrogen relieves vaginal dryness, dyspareunia, and urinary symptoms with minimal systemic absorption. Ospemifene (SERM, oral) is an alternative for women averse to vaginal administration.
• Testosterone therapy (off-label): Transdermal testosterone (cream or patch) at female physiological doses improves HSDD in postmenopausal women. Not FDA-approved for this indication but supported by ISSWSH and RCOG guidelines.
• DHEA (Prasterone/Intrarosa): FDA-approved intravaginal DHEA suppository for moderate-to-severe dyspareunia in postmenopausal GSM. Converts locally to estrogen and testosterone.

Non-Pharmacological Treatments:

• Psychosexual therapy (cognitive behavioural sex therapy): Evidence-based structured therapy addressing psychological barriers, negative cognitions, and relationship factors. Delivered individually or as a couple. Sensate focus exercises form the cornerstone of most sex therapy programmes.
• Pelvic floor physiotherapy: Specialist physiotherapy is first-line for GPPPD, vaginismus, and pelvic floor hypertonia. Includes internal and external manual therapy, biofeedback, dilator therapy, and tailored exercise programmes. Demonstrates excellent outcomes with 70–90% improvement in vaginismus.
• CO2 fractional laser (MonaLisa Touch) / Radiofrequency (ThermiVa): Energy-based devices promote vaginal mucosal remodelling and collagen regeneration for GSM. Moderate evidence supports improvement in vaginal dryness and dyspareunia. Not FDA-approved for this indication; caution advised until long-term data mature.
• Mindfulness-Based Cognitive Therapy (MBCT): Particularly effective for HSDD and orgasmic disorder where spectatoring (self-monitoring during sex) and anxiety are prominent contributors.

Addressing female sexual dysfunction confers benefits extending beyond sexual satisfaction to overall wellbeing:

• Improved sexual satisfaction and relationship quality: Effective treatment of HSDD, dyspareunia, or orgasmic disorder restores sexual intimacy and reduces relationship distress. Studies report significant improvements in Female Sexual Function Index (FSFI) scores following evidence-based treatment.
• Relief from pain: Pelvic floor physiotherapy and appropriate hormonal treatment eliminate or substantially reduce dyspareunia and vaginismus, allowing comfortable intercourse and pelvic examinations.
• Mental health improvements: Sexual dysfunction frequently coexists with depression and anxiety. Resolving sexual health concerns improves mood, self-esteem, and body image.
• Hormonal symptom relief: Topical estrogen therapy for GSM simultaneously relieves vaginal dryness, recurrent UTIs, and urinary urgency — addressing the genitourinary syndrome holistically.
• Improved general quality of life: Sexual health is a component of overall health as recognised by WHO. Restoration of sexual wellbeing contributes to higher scores on validated quality-of-life instruments across physical, social, and emotional domains.
• Relationship preservation: Untreated sexual dysfunction is a significant contributor to relationship breakdown; effective treatment reduces this risk.

Female sexual health treatments are generally safe when appropriately selected, but carry specific considerations:

• Flibanserin (Addyi): Risk of severe hypotension and syncope if taken with alcohol, moderate or strong CYP3A4 inhibitors (ketoconazole, fluconazole), or with certain antidepressants. Prescribers must complete an FDA REMS certification programme. Common side effects: dizziness, somnolence, nausea, and fatigue.
• Bremelanotide (Vyleesi): Nausea (40% of users) requiring pre-treatment antiemetics; transient blood pressure increase (10–12 mmHg systolic) lasting 12 hours — contraindicated in uncontrolled hypertension and cardiovascular disease. Hyperpigmentation of face, gums, and breasts reported with frequent use.
• Topical estrogen: Minimal systemic absorption makes systemic risks negligible; however, the Women's Health Initiative findings regarding systemic HRT do not apply. Endometrial stimulation is not a concern with vaginal-only administration. Theoretical concerns exist for estrogen receptor-positive breast cancer survivors — shared decision-making is required.
• Testosterone (off-label): Risks at physiological doses are minimal. Supraphysiological dosing (acne, hirsutism, voice change, clitoromegaly) must be avoided with regular monitoring of serum testosterone levels.
• Pelvic floor physiotherapy: Occasionally causes temporary increase in pelvic discomfort during initial sessions. Requires a skilled therapist experienced in women's health.
• Energy-based vaginal devices: Potential for vaginal burns with inappropriate device settings; adequate evidence for long-term safety is still accumulating.

Female sexual health management requires structured follow-up to monitor treatment response and adjust care:

• Medical review at 4–8 weeks: Initial follow-up assesses medication tolerability (flibanserin, bremelanotide, topical estrogen), FSFI score change, and patient-reported outcomes. Dose adjustment or medication switching may be warranted.
• Pelvic floor physiotherapy: Typically involves 6–12 sessions over 3 months. Progress is assessed using validated pain scales, pelvic floor muscle assessment, and successful dilator progression for vaginismus. Home exercise compliance is reinforced.
• Psychosexual therapy: Standard programmes span 8–16 sessions. Maintenance sessions at 3 and 6 months after completion consolidate gains. Couples therapy may run concurrently.
• Hormone monitoring: Annual blood tests (estradiol, testosterone, SHBG, FSH) for women on hormonal therapy. Cervical smears and mammography screening continue per national guidelines.
• Long-term wellbeing: Sexual health changes across life stages — pregnancy, postpartum, perimenopause, and ageing. Annual sexual health review as part of well-woman care is recommended by ISSWSH and RCOG. Menopausal transition often requires proactive discussion of GSM management to prevent progression.

Female sexual health care costs vary by treatment modality, clinical setting, and country:

• Psychosexual therapy: In the UK, NHS access is limited; private sessions cost GBP 80–150 per session (typically 8–16 sessions required, total GBP 640–2,400). In the USA, US$100–250 per session. Many insurance plans in the USA cover sex therapy under mental health benefits.
• Pelvic floor physiotherapy: Private physiotherapy in the UK: GBP 60–120 per session; USA: USD 80–200 per session. Course of 8–12 sessions typically needed: USD 640–2,400. NHS waiting times for pelvic floor physiotherapy can be 12–18 months in the UK.
• Flibanserin (Addyi): Approximately USD 800–900/month in the USA without insurance coverage. Generic availability is limited; manufacturer patient assistance programmes exist for eligible patients.
• Topical estrogen: Widely available generically; GBP 5–25/month on NHS prescription; USD 20–80/month in the USA.
• Energy-based devices (CO2 laser): Series of 3 treatments typically required — USD 1,500–3,000 per treatment in the USA; significantly lower in India (INR 15,000–40,000/session) and Turkey.
• Medical tourism: Gynaecological consultations and hormone assessments in India, Thailand, and Turkey cost 60–80% less than equivalent UK or US private care, making comprehensive sexual health evaluation accessible internationally.

Several lifestyle and complementary measures support female sexual health alongside or instead of medical treatments:

• Lubricants and moisturisers: Regular vaginal moisturisers (Replens, Yes VM) maintain pH and elasticity. Water-based or silicone-based lubricants reduce friction-related dyspareunia during intercourse. Safe, effective, and immediately available without prescription.
• Mindfulness and psychological self-help: Mindfulness-based interventions — including the OMT (Online Mindfulness-based Treatment) programme — show efficacy for HSDD and orgasmic disorder. Apps and guided digital programmes provide accessible tools between therapy sessions.
• Lifestyle modifications: Regular cardiovascular exercise improves genital arousal response and body image. Smoking cessation improves vaginal blood flow. Reducing alcohol intake (a sexual depressant at higher doses) improves libido and orgasmic function.
• Nutritional support: Adequate dietary phytoestrogens (soy isoflavones, flaxseed) provide weak estrogenic effects beneficial for mild GSM. Omega-3 fatty acids support cardiovascular health and genital perfusion.
• Relationship and communication skills: Couples communication programmes, relationship counselling, and sexual communication coaching address relational contributors to sexual dysfunction effectively and affordably.